1 Market Overview
1.1 Product Overview and Scope of Cancer Immunotherapy Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Cancer Immunotherapy Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 PD-1 Inhibitor
1.3.3 PDL-1 Inhibitor
1.3.4 T-Cell Stimulant
1.3.5 CTLA Antibody
1.4 Market Analysis by Application
1.4.1 Overview: Global Cancer Immunotherapy Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Cancer Immunotherapy Drug Market Size & Forecast
1.5.1 Global Cancer Immunotherapy Drug Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Cancer Immunotherapy Drug Sales Quantity (2018-2029)
1.5.3 Global Cancer Immunotherapy Drug Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Autolus Therapeutics plc
2.1.1 Autolus Therapeutics plc Details
2.1.2 Autolus Therapeutics plc Major Business
2.1.3 Autolus Therapeutics plc Cancer Immunotherapy Drug Product and Services
2.1.4 Autolus Therapeutics plc Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Autolus Therapeutics plc Recent Developments/Updates
2.2 BeiGene
2.2.1 BeiGene Details
2.2.2 BeiGene Major Business
2.2.3 BeiGene Cancer Immunotherapy Drug Product and Services
2.2.4 BeiGene Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 BeiGene Recent Developments/Updates
2.3 bluebird bio, Inc.
2.3.1 bluebird bio, Inc. Details
2.3.2 bluebird bio, Inc. Major Business
2.3.3 bluebird bio, Inc. Cancer Immunotherapy Drug Product and Services
2.3.4 bluebird bio, Inc. Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 bluebird bio, Inc. Recent Developments/Updates
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb Cancer Immunotherapy Drug Product and Services
2.4.4 Bristol-Myers Squibb Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Bristol-Myers Squibb Recent Developments/Updates
2.5 Celgene Corporation
2.5.1 Celgene Corporation Details
2.5.2 Celgene Corporation Major Business
2.5.3 Celgene Corporation Cancer Immunotherapy Drug Product and Services
2.5.4 Celgene Corporation Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Celgene Corporation Recent Developments/Updates
2.6 AstraZeneca plc
2.6.1 AstraZeneca plc Details
2.6.2 AstraZeneca plc Major Business
2.6.3 AstraZeneca plc Cancer Immunotherapy Drug Product and Services
2.6.4 AstraZeneca plc Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 AstraZeneca plc Recent Developments/Updates
2.7 Gilead Sciences, Inc.
2.7.1 Gilead Sciences, Inc. Details
2.7.2 Gilead Sciences, Inc. Major Business
2.7.3 Gilead Sciences, Inc. Cancer Immunotherapy Drug Product and Services
2.7.4 Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Gilead Sciences, Inc. Recent Developments/Updates
2.8 Incyte Corporation
2.8.1 Incyte Corporation Details
2.8.2 Incyte Corporation Major Business
2.8.3 Incyte Corporation Cancer Immunotherapy Drug Product and Services
2.8.4 Incyte Corporation Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Incyte Corporation Recent Developments/Updates
2.9 Jiangsu Hengrui Medicine
2.9.1 Jiangsu Hengrui Medicine Details
2.9.2 Jiangsu Hengrui Medicine Major Business
2.9.3 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product and Services
2.9.4 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Jiangsu Hengrui Medicine Recent Developments/Updates
2.10 Juno Pharmaceuticals Pty Ltd.
2.10.1 Juno Pharmaceuticals Pty Ltd. Details
2.10.2 Juno Pharmaceuticals Pty Ltd. Major Business
2.10.3 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product and Services
2.10.4 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Juno Pharmaceuticals Pty Ltd. Recent Developments/Updates
2.11 Medimmune, LLC
2.11.1 Medimmune, LLC Details
2.11.2 Medimmune, LLC Major Business
2.11.3 Medimmune, LLC Cancer Immunotherapy Drug Product and Services
2.11.4 Medimmune, LLC Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Medimmune, LLC Recent Developments/Updates
2.12 Merck & Co., Inc.
2.12.1 Merck & Co., Inc. Details
2.12.2 Merck & Co., Inc. Major Business
2.12.3 Merck & Co., Inc. Cancer Immunotherapy Drug Product and Services
2.12.4 Merck & Co., Inc. Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Merck & Co., Inc. Recent Developments/Updates
2.13 Novartis AG
2.13.1 Novartis AG Details
2.13.2 Novartis AG Major Business
2.13.3 Novartis AG Cancer Immunotherapy Drug Product and Services
2.13.4 Novartis AG Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Novartis AG Recent Developments/Updates
2.14 Pfizer, Inc.
2.14.1 Pfizer, Inc. Details
2.14.2 Pfizer, Inc. Major Business
2.14.3 Pfizer, Inc. Cancer Immunotherapy Drug Product and Services
2.14.4 Pfizer, Inc. Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Pfizer, Inc. Recent Developments/Updates
2.15 Roche Holding AG
2.15.1 Roche Holding AG Details
2.15.2 Roche Holding AG Major Business
2.15.3 Roche Holding AG Cancer Immunotherapy Drug Product and Services
2.15.4 Roche Holding AG Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Roche Holding AG Recent Developments/Updates
3 Competitive Environment: Cancer Immunotherapy Drug by Manufacturer
3.1 Global Cancer Immunotherapy Drug Sales Quantity by Manufacturer (2018-2023)
3.2 Global Cancer Immunotherapy Drug Revenue by Manufacturer (2018-2023)
3.3 Global Cancer Immunotherapy Drug Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Cancer Immunotherapy Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Cancer Immunotherapy Drug Manufacturer Market Share in 2022
3.4.2 Top 6 Cancer Immunotherapy Drug Manufacturer Market Share in 2022
3.5 Cancer Immunotherapy Drug Market: Overall Company Footprint Analysis
3.5.1 Cancer Immunotherapy Drug Market: Region Footprint
3.5.2 Cancer Immunotherapy Drug Market: Company Product Type Footprint
3.5.3 Cancer Immunotherapy Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Cancer Immunotherapy Drug Market Size by Region
4.1.1 Global Cancer Immunotherapy Drug Sales Quantity by Region (2018-2029)
4.1.2 Global Cancer Immunotherapy Drug Consumption Value by Region (2018-2029)
4.1.3 Global Cancer Immunotherapy Drug Average Price by Region (2018-2029)
4.2 North America Cancer Immunotherapy Drug Consumption Value (2018-2029)
4.3 Europe Cancer Immunotherapy Drug Consumption Value (2018-2029)
4.4 Asia-Pacific Cancer Immunotherapy Drug Consumption Value (2018-2029)
4.5 South America Cancer Immunotherapy Drug Consumption Value (2018-2029)
4.6 Middle East and Africa Cancer Immunotherapy Drug Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Cancer Immunotherapy Drug Sales Quantity by Type (2018-2029)
5.2 Global Cancer Immunotherapy Drug Consumption Value by Type (2018-2029)
5.3 Global Cancer Immunotherapy Drug Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Cancer Immunotherapy Drug Sales Quantity by Application (2018-2029)
6.2 Global Cancer Immunotherapy Drug Consumption Value by Application (2018-2029)
6.3 Global Cancer Immunotherapy Drug Average Price by Application (2018-2029)
7 North America
7.1 North America Cancer Immunotherapy Drug Sales Quantity by Type (2018-2029)
7.2 North America Cancer Immunotherapy Drug Sales Quantity by Application (2018-2029)
7.3 North America Cancer Immunotherapy Drug Market Size by Country
7.3.1 North America Cancer Immunotherapy Drug Sales Quantity by Country (2018-2029)
7.3.2 North America Cancer Immunotherapy Drug Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Cancer Immunotherapy Drug Sales Quantity by Type (2018-2029)
8.2 Europe Cancer Immunotherapy Drug Sales Quantity by Application (2018-2029)
8.3 Europe Cancer Immunotherapy Drug Market Size by Country
8.3.1 Europe Cancer Immunotherapy Drug Sales Quantity by Country (2018-2029)
8.3.2 Europe Cancer Immunotherapy Drug Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Cancer Immunotherapy Drug Market Size by Region
9.3.1 Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Cancer Immunotherapy Drug Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Cancer Immunotherapy Drug Sales Quantity by Type (2018-2029)
10.2 South America Cancer Immunotherapy Drug Sales Quantity by Application (2018-2029)
10.3 South America Cancer Immunotherapy Drug Market Size by Country
10.3.1 South America Cancer Immunotherapy Drug Sales Quantity by Country (2018-2029)
10.3.2 South America Cancer Immunotherapy Drug Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Cancer Immunotherapy Drug Market Size by Country
11.3.1 Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Cancer Immunotherapy Drug Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Cancer Immunotherapy Drug Market Drivers
12.2 Cancer Immunotherapy Drug Market Restraints
12.3 Cancer Immunotherapy Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Cancer Immunotherapy Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Cancer Immunotherapy Drug
13.3 Cancer Immunotherapy Drug Production Process
13.4 Cancer Immunotherapy Drug Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Cancer Immunotherapy Drug Typical Distributors
14.3 Cancer Immunotherapy Drug Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Cancer Immunotherapy Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Cancer Immunotherapy Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Autolus Therapeutics plc Basic Information, Manufacturing Base and Competitors
Table 4. Autolus Therapeutics plc Major Business
Table 5. Autolus Therapeutics plc Cancer Immunotherapy Drug Product and Services
Table 6. Autolus Therapeutics plc Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Autolus Therapeutics plc Recent Developments/Updates
Table 8. BeiGene Basic Information, Manufacturing Base and Competitors
Table 9. BeiGene Major Business
Table 10. BeiGene Cancer Immunotherapy Drug Product and Services
Table 11. BeiGene Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. BeiGene Recent Developments/Updates
Table 13. bluebird bio, Inc. Basic Information, Manufacturing Base and Competitors
Table 14. bluebird bio, Inc. Major Business
Table 15. bluebird bio, Inc. Cancer Immunotherapy Drug Product and Services
Table 16. bluebird bio, Inc. Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. bluebird bio, Inc. Recent Developments/Updates
Table 18. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 19. Bristol-Myers Squibb Major Business
Table 20. Bristol-Myers Squibb Cancer Immunotherapy Drug Product and Services
Table 21. Bristol-Myers Squibb Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Bristol-Myers Squibb Recent Developments/Updates
Table 23. Celgene Corporation Basic Information, Manufacturing Base and Competitors
Table 24. Celgene Corporation Major Business
Table 25. Celgene Corporation Cancer Immunotherapy Drug Product and Services
Table 26. Celgene Corporation Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Celgene Corporation Recent Developments/Updates
Table 28. AstraZeneca plc Basic Information, Manufacturing Base and Competitors
Table 29. AstraZeneca plc Major Business
Table 30. AstraZeneca plc Cancer Immunotherapy Drug Product and Services
Table 31. AstraZeneca plc Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. AstraZeneca plc Recent Developments/Updates
Table 33. Gilead Sciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 34. Gilead Sciences, Inc. Major Business
Table 35. Gilead Sciences, Inc. Cancer Immunotherapy Drug Product and Services
Table 36. Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Gilead Sciences, Inc. Recent Developments/Updates
Table 38. Incyte Corporation Basic Information, Manufacturing Base and Competitors
Table 39. Incyte Corporation Major Business
Table 40. Incyte Corporation Cancer Immunotherapy Drug Product and Services
Table 41. Incyte Corporation Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Incyte Corporation Recent Developments/Updates
Table 43. Jiangsu Hengrui Medicine Basic Information, Manufacturing Base and Competitors
Table 44. Jiangsu Hengrui Medicine Major Business
Table 45. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product and Services
Table 46. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Jiangsu Hengrui Medicine Recent Developments/Updates
Table 48. Juno Pharmaceuticals Pty Ltd. Basic Information, Manufacturing Base and Competitors
Table 49. Juno Pharmaceuticals Pty Ltd. Major Business
Table 50. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product and Services
Table 51. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Juno Pharmaceuticals Pty Ltd. Recent Developments/Updates
Table 53. Medimmune, LLC Basic Information, Manufacturing Base and Competitors
Table 54. Medimmune, LLC Major Business
Table 55. Medimmune, LLC Cancer Immunotherapy Drug Product and Services
Table 56. Medimmune, LLC Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Medimmune, LLC Recent Developments/Updates
Table 58. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 59. Merck & Co., Inc. Major Business
Table 60. Merck & Co., Inc. Cancer Immunotherapy Drug Product and Services
Table 61. Merck & Co., Inc. Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Merck & Co., Inc. Recent Developments/Updates
Table 63. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 64. Novartis AG Major Business
Table 65. Novartis AG Cancer Immunotherapy Drug Product and Services
Table 66. Novartis AG Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Novartis AG Recent Developments/Updates
Table 68. Pfizer, Inc. Basic Information, Manufacturing Base and Competitors
Table 69. Pfizer, Inc. Major Business
Table 70. Pfizer, Inc. Cancer Immunotherapy Drug Product and Services
Table 71. Pfizer, Inc. Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Pfizer, Inc. Recent Developments/Updates
Table 73. Roche Holding AG Basic Information, Manufacturing Base and Competitors
Table 74. Roche Holding AG Major Business
Table 75. Roche Holding AG Cancer Immunotherapy Drug Product and Services
Table 76. Roche Holding AG Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Roche Holding AG Recent Developments/Updates
Table 78. Global Cancer Immunotherapy Drug Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 79. Global Cancer Immunotherapy Drug Revenue by Manufacturer (2018-2023) & (USD Million)
Table 80. Global Cancer Immunotherapy Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 81. Market Position of Manufacturers in Cancer Immunotherapy Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 82. Head Office and Cancer Immunotherapy Drug Production Site of Key Manufacturer
Table 83. Cancer Immunotherapy Drug Market: Company Product Type Footprint
Table 84. Cancer Immunotherapy Drug Market: Company Product Application Footprint
Table 85. Cancer Immunotherapy Drug New Market Entrants and Barriers to Market Entry
Table 86. Cancer Immunotherapy Drug Mergers, Acquisition, Agreements, and Collaborations
Table 87. Global Cancer Immunotherapy Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 88. Global Cancer Immunotherapy Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 89. Global Cancer Immunotherapy Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 90. Global Cancer Immunotherapy Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 91. Global Cancer Immunotherapy Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 92. Global Cancer Immunotherapy Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 93. Global Cancer Immunotherapy Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 94. Global Cancer Immunotherapy Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 95. Global Cancer Immunotherapy Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 96. Global Cancer Immunotherapy Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 97. Global Cancer Immunotherapy Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 98. Global Cancer Immunotherapy Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 99. Global Cancer Immunotherapy Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 100. Global Cancer Immunotherapy Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 101. Global Cancer Immunotherapy Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 102. Global Cancer Immunotherapy Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 103. Global Cancer Immunotherapy Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 104. Global Cancer Immunotherapy Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 105. North America Cancer Immunotherapy Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 106. North America Cancer Immunotherapy Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 107. North America Cancer Immunotherapy Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 108. North America Cancer Immunotherapy Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 109. North America Cancer Immunotherapy Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 110. North America Cancer Immunotherapy Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 111. North America Cancer Immunotherapy Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 112. North America Cancer Immunotherapy Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 113. Europe Cancer Immunotherapy Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 114. Europe Cancer Immunotherapy Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 115. Europe Cancer Immunotherapy Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 116. Europe Cancer Immunotherapy Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 117. Europe Cancer Immunotherapy Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 118. Europe Cancer Immunotherapy Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 119. Europe Cancer Immunotherapy Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 120. Europe Cancer Immunotherapy Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 121. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 122. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 123. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 124. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 125. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 126. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 127. Asia-Pacific Cancer Immunotherapy Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 128. Asia-Pacific Cancer Immunotherapy Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 129. South America Cancer Immunotherapy Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 130. South America Cancer Immunotherapy Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 131. South America Cancer Immunotherapy Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 132. South America Cancer Immunotherapy Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 133. South America Cancer Immunotherapy Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 134. South America Cancer Immunotherapy Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 135. South America Cancer Immunotherapy Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 136. South America Cancer Immunotherapy Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 137. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 138. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 139. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 140. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 141. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 142. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 143. Middle East & Africa Cancer Immunotherapy Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 144. Middle East & Africa Cancer Immunotherapy Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 145. Cancer Immunotherapy Drug Raw Material
Table 146. Key Manufacturers of Cancer Immunotherapy Drug Raw Materials
Table 147. Cancer Immunotherapy Drug Typical Distributors
Table 148. Cancer Immunotherapy Drug Typical Customers
List of Figures
Figure 1. Cancer Immunotherapy Drug Picture
Figure 2. Global Cancer Immunotherapy Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Cancer Immunotherapy Drug Consumption Value Market Share by Type in 2022
Figure 4. PD-1 Inhibitor Examples
Figure 5. PDL-1 Inhibitor Examples
Figure 6. T-Cell Stimulant Examples
Figure 7. CTLA Antibody Examples
Figure 8. Global Cancer Immunotherapy Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 9. Global Cancer Immunotherapy Drug Consumption Value Market Share by Application in 2022
Figure 10. Hospital Examples
Figure 11. Clinic Examples
Figure 12. Others Examples
Figure 13. Global Cancer Immunotherapy Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Cancer Immunotherapy Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Cancer Immunotherapy Drug Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Cancer Immunotherapy Drug Average Price (2018-2029) & (US$/Unit)
Figure 17. Global Cancer Immunotherapy Drug Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Cancer Immunotherapy Drug Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Cancer Immunotherapy Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Cancer Immunotherapy Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Cancer Immunotherapy Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Cancer Immunotherapy Drug Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Cancer Immunotherapy Drug Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Cancer Immunotherapy Drug Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Cancer Immunotherapy Drug Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Cancer Immunotherapy Drug Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Cancer Immunotherapy Drug Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Cancer Immunotherapy Drug Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Cancer Immunotherapy Drug Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Cancer Immunotherapy Drug Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Cancer Immunotherapy Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 32. Global Cancer Immunotherapy Drug Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Cancer Immunotherapy Drug Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Cancer Immunotherapy Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 35. North America Cancer Immunotherapy Drug Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Cancer Immunotherapy Drug Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Cancer Immunotherapy Drug Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Cancer Immunotherapy Drug Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Cancer Immunotherapy Drug Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Cancer Immunotherapy Drug Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Cancer Immunotherapy Drug Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Cancer Immunotherapy Drug Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Cancer Immunotherapy Drug Consumption Value Market Share by Region (2018-2029)
Figure 55. China Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Cancer Immunotherapy Drug Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Cancer Immunotherapy Drug Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Cancer Immunotherapy Drug Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Cancer Immunotherapy Drug Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Cancer Immunotherapy Drug Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Cancer Immunotherapy Drug Market Drivers
Figure 76. Cancer Immunotherapy Drug Market Restraints
Figure 77. Cancer Immunotherapy Drug Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Cancer Immunotherapy Drug in 2022
Figure 80. Manufacturing Process Analysis of Cancer Immunotherapy Drug
Figure 81. Cancer Immunotherapy Drug Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source

※参考情報 がん免疫療法薬は、がん治療における重要な選択肢として近年注目を集めています。がん免疫療法は、体の免疫システムを活性化させてがん細胞を攻撃することを目的とした治療法です。伝統的な治療法である手術、放射線治療、化学療法とは異なり、がん免疫療法は免疫応答を利用するため、より特異的で持続的な効果をもたらすことが期待されています。 がん免疫療法薬の定義は、体内の免疫系を強化または調整することでがん細胞を攻撃する薬剤を指します。これには、免疫チェックポイント阻害薬、細胞療法、ワクチン療法などが含まれます。近年の研究では、がん細胞が免疫系に対して巧妙に隠れるメカニズムが明らかになり、それに対抗するための新たな治療法が開発されています。 がん免疫療法薬の特徴として、まず挙げられるのはその高い特異性です。従来の化学療法はがん細胞だけでなく、正常細胞にも影響を与えるため副作用が多いですが、免疫療法は特定のがん細胞を狙って攻撃することができます。このため、副作用が少なく、患者の生活の質を維持しやすい点が強みです。 次に、がん免疫療法のもう一つの大きな特徴は、持続的な効果です。免疫系の記憶により、治療後もがん細胞に対する免疫応答が持続する可能性があり、再発や転移を防ぐ要因となります。これにより、長期的な生存率の向上が期待されています。また、がん免疫療法は、特定のがん種に依存せず、一般的には多くの種類のがんに適応可能であることも特徴です。 がん免疫療法薬にはいくつかの種類が存在します。まず、免疫チェックポイント阻害薬は、がん細胞が免疫系の働きを抑えるための「チェックポイント」を阻害することで、免疫系ががん細胞を攻撃できるようにする薬剤です。具体的な例としては、PD-1阻害剤やCTLA-4阻害剤があります。これらの薬剤は、既存のがん治療法では十分に効果が得られなかった患者に対して新たな治療の選択肢を提供しています。 細胞療法は、患者自身の免疫細胞を抽出し、体外で活性化させた後に再び体内に戻す治療法です。特にキメラ抗原受容体T細胞療法（CAR-T療法）は、血液のがんに対して高い治療効果を示していますが、固形腫瘍に対しても研究が進められています。これもまた患者に特異的な治療法の一つであり、個別化医療の進展を体現しています。 さらに、がんワクチン療法も重要なカテゴリーです。これらのワクチンは、特定のがん抗原に対する免疫反応を誘導することで、がん細胞を攻撃する力を高めます。これにより、がんの予防や治療に寄与することが期待されています。最近では、個別化ワクチンも研究されており、患者ごとのがん細胞の異常をもとにしたワクチン開発が進んでいます。 最近のがん免疫療法の進展は、基礎研究だけでなく、臨床応用にも大きな影響を与えています。多くの新薬が臨床試験を経て承認され、様々ながんに対する治療法が確立されつつあります。また、がん免疫療法は単独で使用されるだけでなく、従来の治療法と組み合わせることで効果を高めるアプローチも採られています。これにより、治療効果の向上や副作用の軽減が図られています。 関連技術としては、バイオマーカーの発見とその利用が重要な役割を果たしています。バイオマーカーは、がんの種類や進行度、治療への反応を予測する手助けをするものであり、患者に最適な治療法を選択する際に役立ちます。さらに、データ解析技術の発展により、膨大なデータから新たな治療ターゲットを見つけ出すことが可能になってきています。 がん免疫療法薬は、今後も新たな研究と技術の進展によってさらなる進化を遂げることが期待されます。がんに対する理解が深まるにつれて、より効果的で患者に優しい治療法が提供されることでしょう。これにより、多くのがん患者が新たな希望を持ち、より良い生活を送ることができるようになることが願われています。今後の研究成果に注目が集まります。

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/